Last reviewed · How we verify
AN2728 Topical Ointment, 2% BID
AN2728 is a topical ointment that targets the Janus kinase (JAK) pathway to modulate inflammation.
AN2728 is a topical ointment that targets the Janus kinase (JAK) pathway to modulate inflammation. Used for Moderate to severe plaque psoriasis.
At a glance
| Generic name | AN2728 Topical Ointment, 2% BID |
|---|---|
| Sponsor | Pfizer |
| Drug class | JAK inhibitor |
| Target | JAK |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting JAK enzymes, AN2728 reduces the production of pro-inflammatory cytokines, thereby alleviating symptoms of psoriasis. This mechanism of action is specific to the treatment of moderate to severe plaque psoriasis. AN2728's efficacy in this indication has been demonstrated in clinical trials.
Approved indications
- Moderate to severe plaque psoriasis
Common side effects
- Application site reactions
- Headache
- Nausea
Key clinical trials
- Skin bioMARkers for Atopic Eczema Therapy Evaluation (PHASE2)
- Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo (PHASE2)
- Response of Children With Atopic Dermatitis (Eczema) to Eucrisa (PHASE4)
- A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD (PHASE4)
- Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period
- Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea (PHASE2)
- Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis (PHASE2)
- Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AN2728 Topical Ointment, 2% BID CI brief — competitive landscape report
- AN2728 Topical Ointment, 2% BID updates RSS · CI watch RSS
- Pfizer portfolio CI